XOMA Royalty (XOMA) Total Non-Current Liabilities (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Total Non-Current Liabilities came in at $155.3 million in Q1 2026, up 24.39% year-on-year from $124.8 million in Q1 2025, and down 5.98% quarter-over-quarter from $165.1 million in Q4 2025.
XOMA Royalty (XOMA) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Total Non-Current Liabilities across 16 years of filings, most recently posting $155.3 million for Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $155.3 million, up 24.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $155.3 million (up 24.39% YoY), and the FY2025 annual result was $165.1 million, up 21.3% from the prior year.
- Total Non-Current Liabilities came in at $155.3 million for Q1 2026 at XOMA Royalty, down from $165.1 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $165.1 million in Q4 2025 to a low of $15.0 million in Q1 2023.
- The 4-year median for Total Non-Current Liabilities is $136.1 million (2024), against an average of $127.9 million.
- Across the five-year window, Total Non-Current Liabilities retreated 9.09% in 2025 and gained 24.39% in 2026, its largest moves.
- XOMA Royalty's Total Non-Current Liabilities stood at $15.0 million in 2023, then surged by 807.25% to $136.1 million in 2024, then climbed by 21.3% to $165.1 million in 2025, then declined by 5.98% to $155.3 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $155.3 million (Q1 2026), $165.1 million (Q4 2025), and $151.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | 42,980.09 |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 64.76 Mn |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | 155.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 155.26 Mn |
| Dec 31, 2025 | 165.14 Mn |
| Sep 30, 2025 | 151.69 Mn |
| Jun 30, 2025 | 127.60 Mn |
| Mar 31, 2025 | 124.81 Mn |
| Dec 31, 2024 | 136.14 Mn |
| Sep 30, 2024 | 135.41 Mn |
| Jun 30, 2024 | 140.37 Mn |
| Mar 31, 2023 | 15.01 Mn |
| Sep 30, 2021 | 18.90 Mn |
| Jun 30, 2021 | 19.15 Mn |
| Mar 31, 2021 | 38.07 Mn |
| Dec 31, 2020 | 38.81 Mn |
| Sep 30, 2020 | 47.55 Mn |
| Jun 30, 2020 | 49.43 Mn |
| Mar 31, 2020 | 50.47 Mn |
| Dec 31, 2019 | 51.69 Mn |
| Sep 30, 2019 | 59.85 Mn |
| Jun 30, 2019 | 57.05 Mn |
| Mar 31, 2019 | 51.61 Mn |